tbo-filgrastim
Selected indexed studies
- Tbo-Filgrastim: A Review in Neutropenic Conditions. (BioDrugs, 2016) [PMID:27023705]
- Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor. (Support Care Cancer, 2016) [PMID:26780505]
- Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. (J Clin Oncol, 2015) [PMID:26169616]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Filgrastim induced thrombocytopenia. (2020) pubmed
- Tbo-Filgrastim: A Review in Neutropenic Conditions. (2016) pubmed
- Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor. (2016) pubmed
- Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. (2015) pubmed
- Tbo-filgrastim versus filgrastim for stem cell mobilization and engraftment in autologous hematopoietic stem cell transplant patients: A retrospective review. (2020) pubmed
- Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation. (2015) pubmed
- Conversion from Filgrastim to Tbo-filgrastim: Experience of a Large Health Care System. (2017) pubmed
- Immunogenicity assessment of tbo-filgrastim in cancer patients receiving chemotherapy. (2018) pubmed
- Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors. (2019) pubmed
- Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma. (2017) pubmed